Opal Capital LLC Raises Stake in Merck & Co., Inc. $MRK

Opal Capital LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 321.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,928 shares of the company’s stock after buying an additional 9,098 shares during the period. Opal Capital LLC’s holdings in Merck & Co., Inc. were worth $1,435,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MRK. D.A. Davidson & CO. boosted its stake in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after purchasing an additional 32,114 shares in the last quarter. Norris Perne & French LLP MI increased its stake in shares of Merck & Co., Inc. by 12.8% during the fourth quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock valued at $26,543,000 after purchasing an additional 28,635 shares in the last quarter. Pinnbrook Capital Management LP lifted its holdings in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after purchasing an additional 11,355 shares during the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Merck & Co., Inc. by 32.6% during the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock valued at $137,022,000 after purchasing an additional 320,143 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Up 0.8%

MRK stock opened at $131.85 on Wednesday. The stock has a market capitalization of $325.64 billion, a P/E ratio of 37.14, a P/E/G ratio of 5.19 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $135.05. The business has a fifty day moving average price of $122.39 and a 200-day moving average price of $118.10.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the firm posted $2.22 earnings per share. Merck & Co., Inc.’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported that KEYTRUDA met the primary progression-free-survival endpoint in the Phase 3 KEYNOTE-C93 trial for advanced or recurrent endometrial cancer. The result represents a statistically significant benefit over platinum chemotherapy and could support future regulatory filings, strengthening the company’s oncology pipeline. Merck Says KEYTRUDA Beat Chemotherapy in Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Merck is expanding its growth opportunities beyond KEYTRUDA. A royalty-free licensing agreement will enable generic HIV-prevention treatment supply across 129 low- and middle-income countries, while U.S. approval of LIPFENDRA, described as the first oral PCSK9 inhibitor for LDL reduction, broadens its cardiovascular portfolio. Merck Expands HIV PrEP Access and Launches Oral Cholesterol Drug
• Positive Sentiment: Wells Fargo maintained its Buy rating on MRK, signaling continued confidence in the company’s outlook despite near-term earnings pressure. Wells Fargo Sticks to Its Buy Rating for Merck
• Neutral Sentiment: Brokerage firms collectively assigned Merck an average “Moderate Buy” rating, indicating constructive sentiment but not a unanimous expectation of strong upside. Merck Given Average Moderate Buy Rating by Brokerages
• Negative Sentiment: Analysts expect Merck’s upcoming second-quarter earnings to decline, and previews indicate the company may lack the earnings and revenue momentum typically associated with a likely consensus beat. This could limit near-term gains ahead of the report. Merck Q2 Earnings Expected to Decline

Analyst Ratings Changes

Several research firms recently weighed in on MRK. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, JPMorgan Chase & Co. lifted their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.94.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.